Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Extrinsic Atopic Dermatitis
Brief Summary: The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.


Options:
A: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 100 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo qw
B: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS) | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS) | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Topical Corticosteroid (TCS) | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Dupilumab 300 mg q2w, Placebo qw | Intervention Type: OTHER; Name: Topical Corticosteroid (TCS); Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg qw, Placebo qw
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: REGN668 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 1 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 2 | Intervention Type: BIOLOGICAL; Name: REGN668; Assigned to Arm(s): Cohort 3
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Tralokinumab Dose 1; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 1 | Arm Label: Tralokinumab Dose 2; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 2 | Arm Label: Tralokinumab Dose 3; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 1; Assigned to Arm(s): Tralokinumab Dose 1 | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 2; Assigned to Arm(s): Tralokinumab Dose 2 | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 3; Assigned to Arm(s): Tralokinumab Dose 3

Answer: C